Since a higher TIDE score indicates stronger immune evasion capacity and predicts poorer ICI outcomes, these findings suggest that that elevated HuR expression correlates with a reduced likelihood of therapeutic benefit from ICI therapy, implying enhanced tumor immune evasion capacity. This evidence concerns the gene ELAVL1 and neoplasm.